These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1568578)

  • 21. Novel approach to adherence assessment based on parent drug and metabolite pharmacokinetics: pilot study with spironolactone.
    Pilkova A; Sima M; Hartinger JM; Nikrynova Nguyen TMP; Maresova V; Kurcova I; Slanar O; Widimsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2024 Jun; 168(2):117-123. PubMed ID: 36472169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
    Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
    J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics of cefotaxime in cirrhotic patients with or without ascites].
    Vincent P; Colombel JF; Husson MO; Izard D; Paris JC; Leclerc H
    Presse Med; 1988 Dec; 17(44):2331-4. PubMed ID: 2974968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
    Abosehmah-Albidy AZ; York P; Wong V; Losowsky MS; Chrystyn H
    Br J Clin Pharmacol; 1997 Jul; 44(1):35-9. PubMed ID: 9241094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Furosemide kinetics in patients with hepatic cirrhosis with ascites.
    Fuller R; Hoppel C; Ingalls ST
    Clin Pharmacol Ther; 1981 Oct; 30(4):461-7. PubMed ID: 7285480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers.
    Xu FG; Zhang ZJ; Dong HJ; Tian Y; Liu Y; Chen Y
    Arzneimittelforschung; 2008; 58(3):117-21. PubMed ID: 18488807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of aldactone on potassium storage in patients with ascitic cirrhosis].
    Lévy VG; Lassale B; Del Corso A; Caroli J
    Ann Med Interne (Paris); 1970 Feb; 121(2):183-90. PubMed ID: 5491199
    [No Abstract]   [Full Text] [Related]  

  • 31. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
    Radó JP; Sawinsky I; Juhos E
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of HPTLC and green HPLC methods for determination of furosemide, spironolactone and canrenone, in pure forms, tablets and spiked human plasma.
    Naguib IA; Abdelaleem EA; Emam AA; Ali NW; Abdallah FF
    Biomed Chromatogr; 2018 Oct; 32(10):e4304. PubMed ID: 29855049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spironolactone. I. Disposition and metabolism.
    Karim A; Zagarella J; Hribar J; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
    Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
    Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spironolactone and canrenoate: different antialdosteronic diuretic agents.
    Gentilini P
    Hepatology; 1991 May; 13(5):999-1000. PubMed ID: 2030004
    [No Abstract]   [Full Text] [Related]  

  • 36. [On the pharmacokinetics of spironolactone in the elderly].
    Abshagen U; Platt D; Horn HJ
    Klin Wochenschr; 1981 Aug; 59(16):909-10. PubMed ID: 7278082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fleroxacin pharmacokinetics in patients with liver cirrhosis.
    Blouin RA; Hamelin BA; Smith DA; Foster TS; John WJ; Welker HA
    Antimicrob Agents Chemother; 1992 Mar; 36(3):632-8. PubMed ID: 1622175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased synthesis of systemic prostacyclin in cirrhotic patients.
    Guarner F; Guarner C; Prieto J; Colina I; Quiroga J; Casas J; Freixa R; Rosello J; Gelpi E; Balanzo J
    Gastroenterology; 1986 Mar; 90(3):687-94. PubMed ID: 3510938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites.
    Morali GA; Floras JS; Legault L; Tobe S; Skorecki KL; Blendis LM
    Am J Med; 1991 Oct; 91(4):383-92. PubMed ID: 1835288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.